Search results for "troll"

showing 10 items of 3335 documents

Clinical validation of embryo culture and selection by morphokinetic analysis: a randomized, controlled trial of the EmbryoScope.

2014

Objective To determine whether incubation in the integrated EmbryoScope time-lapse monitoring system (TMS) and selection supported by the use of a multivariable morphokinetic model improve reproductive outcomes in comparison with incubation in a standard incubator (SI) embryo culture and selection based exclusively on morphology. Design Prospective, randomized, double-blinded, controlled study. Setting University-affiliated private in vitro fertilization (IVF) clinic. Patient(s) Eight hundred forty-three infertile couples undergoing intracytoplasmic sperm injection (ICSI). Intervention(s) No patient intervention; embryos cultured in SI with development evaluated only by morphology (control …

Adultmedicine.medical_specialtyAdolescentEarly Pregnancy Lossmedicine.medical_treatmentSensitivity and SpecificityTime-Lapse ImagingIntracytoplasmic sperm injectionlaw.inventionEmbryo Culture TechniquesIncubatorsYoung AdultHuman fertilizationFetoscopesRandomized controlled triallawPregnancyObstetrics and GynaecologymedicineHumansGynecologyPregnancyMicroscopy Videobusiness.industryPregnancy OutcomeObstetrics and GynecologyReproducibility of ResultsEmbryo cultureEquipment Designmedicine.diseaseEmbryo TransferEmbryo MammalianClinical trialEquipment Failure AnalysisPregnancy rateReproductive MedicineFemalebusinessInfertility FemaleFertility and sterility
researchProduct

Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial

2015

Objective: To report and discuss the multi-domain impact of elosulfase alfa, with focus on tertiary and composite endpoints, in the 24-week, randomized, double-blind, placebo-controlled phase 3 trial in patients with Morquio A syndrome (mucopolysaccharidosis IVA). Methods: Patients with Morquio A syndrome >= 5 aged years were randomized 1:1:1 to elosulfase alfa 2.0 mg/kg/week (qw; N = 58), elosulfase alfa 2.0 mg/kg/every other week (qow; N = 59), or placebo (N = 59) for 24 weeks. Primary and secondary efficacy measures were 6-minute walk test (6MWT; primary), 3-minute stair climb test (3-MSCT) and urinary keratan sulfate (KS). Safety was also evaluated. Tertiary efficacy measures included r…

Adultmedicine.medical_specialtyAdolescentIdursulfaseMucopolysaccharidosisEndocrinology Diabetes and MetabolismPlaceboBiochemistrylaw.inventionYoung Adultchemistry.chemical_compoundEndocrinologyDouble-Blind MethodRandomized controlled trialElosulfase alfalawSurveys and QuestionnairesInternal medicineActivities of Daily LivingmedicineGeneticsHumansEnzyme Replacement TherapyRespiratory functionYoung adultChildMolecular Biologybusiness.industryMucopolysaccharidosis IVMaximal Voluntary VentilationMiddle Agedmedicine.diseaseBody HeightChondroitinsulfatasesRespiratory Function TestsTreatment OutcomechemistryChild PreschoolPhysical therapyPopulation studybusinessmedicine.drugMolecular genetics and metabolism
researchProduct

Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease

1993

Abstract Background: The role of azathioprine (AZA) in the treatment of active Crohn's disease (CD) is still controversial. This study examined whether AZA combined with standard prednisolone therapy improved the therapeutic outcome compared with monotherapy with prednisolone. Methods: Forty-two patients with a Crohn's Disease Activity Index (CDAI) of > 150 were randomized into two groups. Both received 60 mg of prednisolone daily in a tapering regimen to a maintenance dose of 10 mg. In addition, group 1 received 2.5 mg AZA/kg body wt and group 2 received a placebo over the whole study period of 4 months. Results: At the end of the trial, 16 of 21 patients (76%) in group 1 were in remission…

Adultmedicine.medical_specialtyAdolescentPrednisolonemedicine.medical_treatmentAzathioprinePlaceboGastroenterologylaw.inventionCrohn DiseaseRandomized controlled triallawInternal medicineAzathioprinemedicineHumansChemotherapyHepatologybiologyMaintenance dosebusiness.industryC-reactive proteinGastroenterologyMiddle AgedSurgeryRegimenTreatment OutcomePrednisolonebiology.proteinDrug Therapy Combinationbusinessmedicine.drugGastroenterology
researchProduct

Bed rest after embryo transfer negatively affects in vitro fertilization: a randomized controlled clinical trial.

2013

Objective To evaluate the influence of 10 minutes of bed rest after ET on the achievement of a live-born infant (LBI) in patients undergoing IVF treatment with oocyte donation (OD). Design Prospective, randomized, parallel assignment, controlled trial. Setting Private IVF center. Patient(s) A total of 240 patients undergoing a first IVF cycle with OD in our center. Intervention(s) Ten minutes of bed rest after ET or no bed rest, that is, allowing patients to ambulate immediately after the ET. Main Outcome Measure(s) The primary outcome was LBI rate per randomized patient. Secondary outcomes were implantation rate and biochemical and clinical miscarriage rates. Result(s) LBI rates (56.7% vs.…

Adultmedicine.medical_specialtyAdolescentPregnancy Ratemedicine.medical_treatmentFertilization in VitroBed restMiscarriagelaw.inventionYoung AdultRandomized controlled triallawPregnancyStatistical significancemedicineHumansEmbryo ImplantationPostoperative PeriodGynecologybusiness.industryInfant NewbornObstetrics and GynecologyMiddle Agedmedicine.diseaseEmbryo TransferEmbryo transferClinical trialPregnancy rateReproductive MedicineAnesthesiaInfertilityApgar scoreFemalebusinessAlgorithmsBed RestFertility and sterility
researchProduct

Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with hep…

2010

Abstract Introduction The aim of this study was to assess the effect of thrombolysis versus heparin treatment on echocardiographic parameters and clinical outcome, during hospitalization and within the first 180 days after admission, in patients with first episode of submassive pulmonary embolism (SPE) and right ventricle dysfunction (RVD). Methods Consecutive patients (age, 18–75 years) with a first episode of SPE, symptoms onset since no more than 6 hours, normal blood pressure (> 100 mm Hg), echocardiographic evidence of RVD and positive lung spiral computed tomography were double-blind randomized: 1 group received 100 mg of alteplase (10-mg bolus, followed by a 90-mg intravenous infusio…

Adultmedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentVentricular Dysfunction RightPlacebolaw.inventionYoung AdultRandomized controlled trialDouble-Blind MethodFibrinolytic AgentslawInternal medicineFibrinolysismedicineHumansThrombolytic TherapyAgedFirst episodebusiness.industryHeparinAnticoagulantpulmonary embolism echocardiographyAnticoagulantsGeneral MedicineHeparinThrombolysisMiddle Agedmedicine.diseaseSurgeryPulmonary embolismEchocardiographyTissue Plasminogen ActivatorCardiologyWarfarinbusinessPulmonary Embolismmedicine.drugThe American journal of the medical sciences
researchProduct

Effectiveness of cognitive behavioral therapy supported by virtual reality in the treatment of body image in eating disorders: One year follow-up

2013

Body image disturbance is a significant maintenance and prognosis factor in eating disorders. Hence, existing eating disorder treatments can benefit from direct intervention in patients' body image. No controlled studies have yet compared eating disorder treatments with and without a treatment component centered on body image. This paper includes a controlled study comparing Cognitive Behavioral Treatment (CBT) for eating disorders with and without a component for body image treatment using Virtual Reality techniques. Thirty-four participants diagnosed with eating disorders were evaluated and treated. The clinical improvement was analyzed from statistical and clinical points of view. Result…

Adultmedicine.medical_specialtyAdolescentmedicine.medical_treatmentAnorexialaw.inventionFeeding and Eating DisordersYoung AdultRandomized controlled triallawIntervention (counseling)Body ImagemedicineHumansBiological PsychiatryCognitive Behavioral TherapyBulimia nervosaVirtual Reality Exposure TherapyCognitionmedicine.diseasePersonality disordersCognitive behavioral therapyPsychiatry and Mental healthEating disordersTreatment OutcomePhysical therapyFemalemedicine.symptomPsychologyAttitude to HealthFollow-Up StudiesClinical psychologyPsychiatry Research
researchProduct

Evidence of bias in randomized clinical trials of hepatitis C interferon therapies

2017

Introduction: Bias may occur in randomized clinical trials in favor of the new experimental treatment because of unblinded assessment of subjective endpoints or wish bias. Using results from published trials, we analyzed and compared the treatment effect of hepatitis C antiviral interferon therapies experimental or control. Methods: Meta-regression of trials enrolling naïve hepatitis C virus patients that underwent four therapies including interferon alone or plus ribavirin during past years. The outcome measure was the sustained response evaluated by transaminases and/or hepatitis C virus-RNA serum load. Data on the outcome across therapies were collected according to the assigned arm (exp…

Adultmedicine.medical_specialtyAlternative medicineAntiviral Agentslaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialBiaslawInterferonInternal medicinemedicineHumans030212 general & internal medicineSettore SECS-S/05 - Statistica SocialeRandomized Controlled Trials as TopicPharmacologyObserver Variationbusiness.industryGeneral MedicineHepatitis CMiddle Agedmedicine.diseaseHepatitis Cinterferon randomized controlled trials bias trial design favore armTreatment OutcomeResearch Design030220 oncology & carcinogenesisCase-Control StudiesPhysical therapyInterferonsbusinessmedicine.drug
researchProduct

Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer

2007

Patients with cervical cancer frequently suffer from anemia. This two-stage, adaptive-design study investigated the effect of anemia correction with epoetin beta on treatment outcomes. Patients with stage IIB–IVA cervical cancer received radiochemotherapy (RCT) and were randomized to epoetin 150 IU/kg three times weekly (n = 34) or standard care (control; n = 40) for up to 12 weeks. Primary end point for stage 1 aimed to establish a correlation between anemia correction and treatment failure (no complete response or relapsing within 6 months after RCT initiation) as a proof of concept before moving into stage 2. Secondary end points included progression/relapse-free survival, overall surviv…

Adultmedicine.medical_specialtyAnemiaInjections Subcutaneousmedicine.medical_treatmentUterine Cervical NeoplasmsRisk AssessmentGastroenterologyDrug Administration Schedulelaw.inventionRandomized controlled trialReference ValueslawInternal medicinemedicineClinical endpointHumansAdverse effectErythropoietinSurvival analysisNeoplasm StagingProbabilityCervical cancerChemotherapyEpoetin betaDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyAnemiaMiddle Agedmedicine.diseaseCombined Modality TherapyImmunohistochemistrySurvival AnalysisRecombinant ProteinsSurgeryLogistic ModelsTreatment OutcomeOncologyChemotherapy AdjuvantFemaleRadiotherapy AdjuvantbusinessFollow-Up StudiesInternational Journal of Gynecologic Cancer
researchProduct

Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients

2016

Background Invasive fungal infections are important causes of morbidity and mortality among critically ill patients. Early institution of antifungal therapy is pivotal for mortality reduction. Starting a targeted antifungal therapy after culture positivity and fungi identification requires a long time. Therefore, alternative strategies (globally defined as 'untargeted antifungal treatments') for antifungal therapy institution in patients without proven microbiological evidence of fungal infections have been discussed by international guidelines. This review was originally published in 2006 and updated in 2016. This updated review provides additional evidence for the clinician dealing with s…

Adultmedicine.medical_specialtyAntifungal drugMycoseintensive care medicinelaw.invention03 medical and health sciencesImmunocompromised Hostcritically ill patient0302 clinical medicineRandomized controlled triallawInternal medicineAmphotericin BmedicineHumansAntifungal AgentPharmacology (medical)030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineFluconazoleFluconazole [therapeutic use]Randomized Controlled Trials as Topicbusiness.industryfungal infectionMicafungin030208 emergency & critical care medicinePublication biasMycoses [mortalityClinical trialCritical Illness [mortality]; Amphotericin B [therapeutic use]; Antifungal Agents [therapeutic use]; Fluconazole [therapeutic use]; Immunocompromised Host; Mycoses [mortality; prevention & control]; Randomized Controlled Trials as Topic; Adult; HumansAntifungal Agents [therapeutic use]prevention & control]Relative riskMeta-analysisAmphotericin B [therapeutic use]AnidulafunginCritical IllneCritical Illness [mortality]businessmedicine.drugHuman
researchProduct

A comparison of the effectiveness of azelaic and pyruvic acid peels in the treatment of female adult acne: a randomized controlled trial

2020

AbstractChemical peels are widely used as therapeutic agents in dermatology and cosmetology. This study aims to explore the differences in the effectiveness of azelaic and pyruvic acid peels in the treatment of acne vulgaris. Eligibility criteria for participants were: female gender, 18–25 years of age, no dermatological treatment within the last 12 months and mild to moderate papulopustular acne. We treated 120 young women (with a mean age of 22 years old) with six peeling sessions at 2-week intervals. In the parallel clinical study design, one randomized group (n = 60, 50%) was treated using azelaic acid (AA), whereas the second group participated in pyruvic acid (PA) sessions. We evaluat…

Adultmedicine.medical_specialtyAzelaic acidScienceDiseasesArticlelaw.inventionDesquamation030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicineRandomized controlled trialPapulopustularlawAcne VulgarisPyruvic AcidmedicineHumansDicarboxylic Acids030212 general & internal medicineAcneSkinAnalysis of VarianceMultidisciplinarybusiness.industryQRmedicine.diseaseDermatologySkin diseasesTreatment OutcomechemistryMedicineFemaleCosmetologyPyruvic acidmedicine.symptombusinessPorosityAfter treatmentmedicine.drugScientific Reports
researchProduct